Premier Alternatives

Bond Biosciences

Parkville, MO · Founded 2015 · Privately Held (backing)

Developer of small molecule-based therapeutics designed to prevent and treat ion-related human diseases. Bond Biosciences is based in Parkville, MO and was founded in 2015. Its last reported valuation was $122 million in Jan 2022. It has raised $17.1 million across 2 recorded rounds; the latest was a $5.9 million early-stage round in Apr 2026.

Last reported valuation
$121.8M
Oct 2026
Priced at
—
Total raised
$17.1M
Last round
Early Stage VC
Apr 2026

Bond Biosciences key facts

as of Oct 2026
  • Developer of small molecule-based therapeutics designed to prevent and treat ion-related human diseases.
  • Bond Biosciences is valued at approximately $121.8M as of Oct 2026 (last reported valuation).
  • It has raised $17.1M across 2 recorded rounds; the latest was Early Stage VC ($5.9M) in Apr 2026.
  • Notable investors include National Institutes of Health, BioGenerator Ventures, Collage Venture Partners, Emerald Bioventures, Transhuman Capital.
  • Bond Biosciences has filed 4 Form Ds with the SEC since 2024, most recently Jan 2026 ($4.5M sold to 91 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$121.8M

Bond Biosciences's last reported valuation, Jan 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Bond Biosciences with a free account
  • ·Watch Bond Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Bond Biosciences funding rounds

2 rounds
Apr 2026Early Stage VC$5.9MSEC filing▮
Aug 2024Seed Round$4.5MSEC filing▮
Full funding history →

Bond Biosciences valuation

Bond Biosciences's last reported valuation was $122 million in Jan 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Bond Biosciences raised?

Bond Biosciences has raised $17.1 million in total; 2 of its rounds are on record. The largest on record was a $5.9 million early-stage round in Apr 2026.

Bond Biosciences has filed 4 Form Ds with the SEC since 2024, most recently in Jan 2026 ($4.5 million sold to 91 investors).

Bond Biosciences investors

5 investors are on record for Bond Biosciences, including National Institutes of Health, BioGenerator Ventures, Collage Venture Partners and Emerald Bioventures. The early-stage round in Apr 2026 drew 83 investors.

About Bond Biosciences

Developer of small molecule-based therapeutics designed to prevent and treat ion-related human diseases. The company offers polymer-based compounds, targeted ion-binding mechanisms, and oral drug candidates, enabling patients with ion-related conditions to manage disease progression and reduce complications.

Sector
Healthcare
HQ
Parkville, MO, United States
Founded
2015
Employees
3
Website
bond.bio/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.